SCHEMBL1204483

SCHEMBL1204483

CCCN(CCC)CCCCNS(=O)(=O)c1ccc(CN2C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
CA1 P00915 1/20 0.49
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
DRD3 P35462 1/20 0.46
ALDH1A1 P00352 2/20 0.42
USP2 O75604 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
MAOB P27338 1/20 0.41
CASP3 P42574 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205682 0.82 CA12 (0.51) CA12CA2CA9CA1DRD3
SCHEMBL1205373 0.82 ACHE (0.53) DRD3ACHE
SCHEMBL7128177 0.80 CA1 (0.62) CA12CA2CA9CA1ALDH1A1
SCHEMBL1206331 0.78 USP2 (0.50) CA12CA2CA9CA1TSHR
SCHEMBL1206414 0.75 BRD4 (0.58) CA12CA2CA9CA1TSHR
SCHEMBL1204490 0.75 ALDH1A1 (0.45) TSHRTDP1DRD3ALDH1A1USP2
SCHEMBL23718102 0.74 CA12 (0.61) CA12CA2CA9ALDH1A1USP2
SCHEMBL1206144 0.73 DRD3 (0.50) TSHRDRD3BCHEACHEMAOB
SCHEMBL7095382 0.73 HTR1A (0.58) CA12CA2CA9ALDH1A1USP2
SCHEMBL1206411 0.71 BCHE (0.52) TSHRDRD3SIGMAR1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 US disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 CA12 2976/4885CA2 4598/4885CA9 4304/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 CA12 1427/4885CA2 4385/4885CA9 2930/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 CA12 2935/4885CA2 3591/4885CA9 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.